Showing 221 - 240 results of 81,334 for search '(( 01 0 decrease ) OR ( 50 ((((a decrease) OR (we decrease))) OR (nn decrease)) ))', query time: 1.15s Refine Results
  1. 221

    Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

    Published 2025
    “…</i> Total proximal axonal length is decreased in cuprizone-treated PFC PV interneurons compared with control cells (<i>t test; n = 10/9 cells per group, **p < 0.01</i>)<i>. …”
  2. 222
  3. 223
  4. 224
  5. 225
  6. 226
  7. 227
  8. 228
  9. 229
  10. 230
  11. 231

    β<sub>2</sub>-Agonist Induced cAMP Is Decreased in Asthmatic Airway Smooth Muscle Due to Increased PDE4D by Thomas Trian (221535)

    Published 2011
    “…</p> <h3>Results</h3><p>In the presence of IBMX, a pan PDE inhibitor, asthmatic ASM had ∼50% lower cAMP production in response to isoproterenol, albuterol, formoterol, and forskolin compared to non-asthmatic ASM. …”
  12. 232
  13. 233
  14. 234
  15. 235

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  16. 236

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  17. 237

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  18. 238

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  19. 239

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Although many promising chemotherapeutics have been developed upon the basis of polyaromatic DNA intercalating systems, these candidates did not proceed past clinical trials on account of their dose-limiting toxicity. Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. …”
  20. 240

    S2 File - by Yosuke Kameno (342665)

    Published 2023
    “…This initial increase and subsequent decrease in K6 and FCV-19S were more prominent in individuals with high trait anxiety (K6: B = 1.55, 95% CI = 1.18 to 1.91; FCV-19S: B = 4.27, 95% CI = 2.50 to 6.04) and in occupations other than physicians or nurses. …”